Ms. T is a 38-year-old woman who presents with a 6-month history of heavy menstrual bleeding and fatigue. Her lab results show low hemoglobin, ferritin, iron, MCV and MCH levels consistent with iron deficiency anemia. Her risk factors include female gender, past pregnancies, long-term NSAID use, and intermenstrual bleeding. She is started on iron supplements to replenish her iron stores, treat her anemia, and resolve her symptoms.

1. IRON DEFICIENCY
ANEMIA CASE STUDY

2. PATIENT INTRODUCTION
 Ms. T is a 38 year old white woman who presents to her
Nurse Practitioner complaining of 6 month history of
intermenstrual bleeding and menorrhagia accompanied with
extreme fatigue and weakness. Her month periods now
included 8-10 days of bleeding and cramping.
 Medical history: G2 P2, uses NSAIDS regularly for left knee
pain from previous sport injury as teen.
 Family history: non contributory

3. PHYSICAL EXAM AND LAB
RESULTS
 Height – 5’5 inches
 BP 130/80
 Pulse 98 regular
 Chest clear
 Lifelabs Medical Laboratories (2017)
Patients results Normal values
female
Hb 91 115 - 155
Hct .29 0.35 - 0.45
RBC 3.3 3.5 - 5
MCV 71 82 - 98
MCH 19 27.5 - 33.5
MCHC 27 300 -370
WBC 7.9 4 -10
Ferritin 9.7 24 – 444
Iron 8 11 - 33

4. DIFFERENTIAL DIAGNOSES
 Depression
 Hypothyroidism
 GI bleed
 Cancer (Chronic disease anemia)
 Chronic Myeloid Leukemia
 Beta Thalassemia minor
 Poor diet (malnutrition)

5. HEMOGRAM OF IRON DEFICIENCY
ANEMIA AND DDX FROM OTHER
ANEMIAS
IDA ACD VBD
Ferritin
︎⇩ ⇧ normal
Iron
⇩ ⇩ normal
MCV/ MCH
⇩ Usually
normal to
decreased
⇧
 Iron deficiency anemia (IDA)
 Anemia of Chronic Disease (ACD)
 Vit B12 deficiency (VBD)
(Schrier & Camaschella, 2017)

6. PATHOPHYSIOLOGY OF THE
DISEASE
Iron is a crucial element for hemoglobin production, its
necessity is especially high in kids and pregnant women due
high demand. Iron deficiency is the most common cause for
anemia in general population, anemia becomes evident when
Iron stores in a form of Ferritin are depleted. Since the biggest
source of Iron for building new Hb recycled from old RBC, even
a small amount of chronic bleeding can lead to anemia.
(Schrier, 2017)

7. THE NORMAL IRON CYCLE
Iron absorbed from the small
intestine or released from storage
or available from catabolism of
old RBC
Then iron attached to a
protein transferrin and
transported to bone marrow
for Hb synthesis
Excess Iron stored by the
liver in form of Ferritin
As RBC age, they get
destroyed by macrophages in
the spleen and iron gets
recycled into plasma
(McCane & Huether, 2014, p.964)

8. TREATMENT GOALS
 Investigate the cause of anemia and loss of Iron stores
 Patient education regarding her new diagnoses, treatment options
and prognoses.
 Correct anemia and Iron stores with supplements
 Watch for treatment compliance
 Diet counseling

9. PATIENT SPECIFIC TREATMENT
 Diet counseling
 Investigate the cause of prolonged intermenstrual bleeding, stop the use of
NSAIDS if possible and rule out GI bleed .
 Educate the patient how to use Iron supplements and about its side
effects.
 Advise patient to keep Iron supplements away from children (overdose is
toxic)
 Start supplementing with Iron supplements in conjunction with vitamin C.

10. INITIATING THERAPY
 Can start from 180 mg elemental Iron a day and
regulate the dose based on patients tolerance and
severity of anemia. It is recommended to start with a
lower dose to ease up on side effects and slowly go
up.
 Order CBC and Ferritin, and see the patient again in 2-
4 weeks
 Continue treatment for 3-6 month. Supplementing
beyond 6 month is not recommended

11. AVAILABLE IRON PREPARATIONS
There is no preference to a specific agent, however sustained
release products may not be as effective as regular product.
Iron salt Formulation
(elemental iron)
Adult dose Side
effects
Cost per
month
Ferrous sulfate Tab 300mg (60mg) 1tab Q3D +++ 2-3$
Sustained release Tab
160mg(50mg)
1-4 tab OD + 25$
Suspension 75mg/ml
(15mg/ml)
4ml Q3D ++ 100$
Syrup 30mg/ml
(6mg/ml)
10ml Q3D ++ 3-5$
(BCGuidelines, 2015, Appendix B)

12. AVAILABLE IRON PREPARATIONS
CONT.
Iron Salt Formulation
(elemental Iron)
Adult dose Side
effects
Cost per
month
(Pharmacare
coverage)
Ferrous
Gluconate
Tab 300mg
(35mg)
1-3 tab 2-3
times a day
++ 3-5$
Ferrous
Fumarate
Tab 300mg
(90mg)
1 tab Q2D ++ 2-20$
Suspension
300mg/5ml
(20mg/ml)
3 ml Q3D ++ 35$
Polysacchari
de
Iron
Capsules 150mg
(150mg)
1 caps OD + 24$
(BCGuidelines, 2015, Appendix B)

13. SIDE EFFECTS
Iron supplements associated with many side effects,
therefore clinician should watch for compliance.
Side effects include:
Nausea
Vomiting
Dyspepsia
Constipation/ Diarrhea
Dark stools
Bloating
(BCGuidelines, 2015, Appendix B)

14. DRUG-DRUG AND FOOD-DRUG
INTERACTIONS
 Iron absorbed best in acid environment, therefore any food or
medication that can increase gastric PH will interfere with proper
absorption.
 Iron can interfere with absorption of other drugs, best given alone.
 Food interaction: Cereals, dietary fiber, tea, coffee, eggs and milk
may decrease absorption

15. PATIENT SPECIFIC RISK FACTORS
Ms T. is at risk for anemia for several factors:
 Female of child baring age
 Was pregnant twice
 Long intermenstrual bleeding
 Long term use of NSAIDS

16. EPIDEMIOLOGY
Overall Iron deficiency is the most common reason for anemia, it
affects over 12 percent of the population, and more prevailing in third
world countries due to poor diet (Schrier, 2017).
Who is at risk?
 Infants
 Children
 Women
 Elderly
 People with certain conditions

17. EPIDEMIOLOGY CONT.
Causes for
iron
deficiency
Poor
absorption
Inadequate
intake and
high
demand
Blood
loss
o Chronic bleeding
o Heavy period
o Frequent blood
donor
o Celiac disease
o Gastric surgery
o Gastric ulcer
o Gastric
parasites
o Poor diet
o Vegetarian diet
o Pregnancy/lactati
on
o Growth sprout
(Schrier,2017)

18. REFERENCE
 Benz, E., 2017. Clinical Manifestations and Diagnosis of the Thalassemias.
UptoDate. Retrieved from https://www.uptodate.com/contents/clinical-
manifestations-and-diagnosis-of-the-
thalassemias?source=search_result&search=beta%20thalassemia%20minor&sel
ectedTitle=1~14
 British Columbia Guidelines, 2015. Iron Deficiency – Investigation and
Management. Retrieved from
http://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-
guidelines/iron-deficiency
 Dietitians of Canada, 2016. Food sources of Iron. Retrieved from
http://www.dietitians.ca/Your-Health/Nutrition-A-Z/Minerals/Food-Sources-of-
Iron.aspx
 Ross, D., 2017. Diagnosis of and Screening for Hypothyroidism in Non Pregnant
Adults. Uptodate. Retrieved from https://www.uptodate.com/contents/diagnosis-
of-and-screening-for-hypothyroidism-in-nonpregnant-
adults?source=search_result&search=hypothyroidism&selectedTitle=1~150
 LifeLabs, 2017. Reference Range. Retrieved from
http://www.lifelabs.com/healthcare-providers/Pages/Reference-Ranges.aspx
 McCance, K., & Huether, S.,2014, p.964. The Hematologic System.
Pathophysiology: the Biologic Basis for Disease in Adults and Children.

19. REFERENCE CONT.
 Schrier, S., 2017. Causes and Diagnosis of Iron Deficiency and Iron
Deficiency Anemia in Adults. UptoDate. Retrieved from
https://www.uptodate.com/contents/causes-and-diagnosis-of-iron-
deficiency-and-iron-deficiency-anemia-in-
adults?source=search_result&search=iron%20deficiency%20anemia
&selectedTitle=1~150
 Schrier, S., Camaschella, C., 2017. Anemia of Chronic
Disease/Inflammation. UptoDate. Retrieved from
https://www.uptodate.com/contents/anemia-of-chronic-disease-
inflammation?source=search_result&search=anemia%20of%20chroni
c&selectedTitle=1~150
 Van Etten, R., 2017. Clinical Manifestations and Diagnosis of Chronic
Myeloid Leukemia. UptoDate. Retrieved from
https://www.uptodate.com/contents/clinical-manifestations-and-
diagnosis-of-chronic-myeloid-
leukemia?source=search_result&search=chronic%20myeloid%20leuk
emia&selectedTitle=1~150